Share Name Share Symbol Market Type Share ISIN Share Description
Hikma Pharmaceuticals Plc LSE:HIK London Ordinary Share GB00B0LCW083 ORD SHS 10P
  Price Change % Change Share Price Shares Traded Last Trade
  0.00 0.0% 2,383.00 0.00 01:00:00
Bid Price Offer Price High Price Low Price Open Price
2,393.00 2,395.00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 1,712.25 408.13 133.56 18.2 5,493
Last Trade Time Trade Type Trade Size Trade Price Currency
- O 0 2,383.00 GBX

Hikma Pharmaceuticals (HIK) Latest News

More Hikma Pharmaceuticals News
Hikma Pharmaceuticals Investors    Hikma Pharmaceuticals Takeover Rumours

Hikma Pharmaceuticals (HIK) Discussions and Chat

Hikma Pharmaceuticals Forums and Chat

Date Time Title Posts
30/4/202114:49Hikma Pharmaceuticals1,183
13/1/201515:12 *** Hikma ***98

Add a New Thread

Hikma Pharmaceuticals (HIK) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
2021-06-24 15:25:102,394.00247.88AT
2021-06-24 15:25:102,394.0021502.74AT
2021-06-24 15:25:102,394.00731,747.62AT
2021-06-24 15:24:492,394.72461,101.57O
2021-06-24 15:24:432,395.00992,371.05AT
View all Hikma Pharmaceuticals trades in real-time

Hikma Pharmaceuticals (HIK) Top Chat Posts

Hikma Pharmaceuticals Daily Update: Hikma Pharmaceuticals Plc is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker HIK. The last closing price for Hikma Pharmaceuticals was 2,372p.
Hikma Pharmaceuticals Plc has a 4 week average price of 2,343p and a 12 week average price of 2,275p.
The 1 year high share price is 2,766p while the 1 year low share price is currently 2,087p.
There are currently 230,495,233 shares in issue and the average daily traded volume is 389,151 shares. The market capitalisation of Hikma Pharmaceuticals Plc is Ā£5,492,701,402.39.
haroldthegreat: In the uk the .generics have taken a large share of the market. drs are told to prescribe by the branded name of the generic so as to reduce the costs for the nhs . Also to ensure the patient receives the same brand each time. There is a large demand in the States and if the product is priced competitively it should increase the companies turnover and profitability .
haroldthegreat: Prices from 105 to 321 for the brand from a pharmacy in the states. Coupons are used to reduce the price See below hxxps://
haroldthegreat: Have been waiting for news re generic advair launch but share price response has been poor today. Have also discovered gsk launched their own cheaper generic years ago . Does anyone know the relative prices of their brand and their own generic in the states . ADVAIR DISKUS Authorized Generic Statement GSK Announces Availability of Authorized Generic ADVAIR DISKUSĀ® (fluticasone propionate/salmeterol inhalation powder) February 8th, 2019 GSK announced today plans to make available an authorized generic (AG) of ADVAIR DISKUS (fluticasone propionate/salmeterol inhalation powder) in all three approved strengths. The authorized generic will be manufactured by GSK and distributed by Prasco LLC. The authorized generic contains the same medicines in the same DISKUS device familiar to patients with the same instructions for use as ADVAIR DISKUS. Obviously the generic will cost very little to produce relative to the prices charged. How many other copies are available in the states at the moment .
suetballs: Perhaps hik and others could step in? Would seem sensible to me. Suet
thewheeliedealer: Hi all, My mate Peter @Conkers3 and myself did a ‘Twin Petes Investing’ Podcast a few days before Xmas and part of our discussion includes HIK which I know C3 is keen on. We also chatted about loads of other Stocks and Ideas for research. We discussed the outlook for Markets and the most likely roadmap for the next couple of months, and as usual a fair bit of educational stuff with regards to Investing. Anyway, if you use Youtube, Apple, Audioboom, Overcast or Spotify you can find it under the 'Conkers Corner' Channel (you want Podcast TPI 38) and you can find it on Soundcloud at the link below. I hope you enjoy it and find it useful, we try to keep them light and they are totally unscripted, not like all the stuffy financial fodder you are probably more used to !! Season’s Greetings !! WD @wheeliedealer hTTps://
montyhedge: I like Hik. All I'm saying the pie in Advair seems to me will be small for everyone, if undercutting goes on.
suetballs: Well monty buy some hik to hedge your bets. I own both shares. Suet
polaris: Montyhedge - are you serious? Mylan (now Viatris) launched a generic Advair in January 2019. The total GSK sales of Advair in the US are less than half of what they were in late 2018. Mylan aggressively price cut and took significant market share. The Hikma/VEC product will just exacerbate this margin cut. If you are going to make a comment, at least look at the market before punting BS. edit I'll lay it out for you, nice and simple. GSK US Advair sales: 2017 £1.61 Bn 2018 £1.097 Bn 2019 £502 M 2020 ytd £361 M GSK reduced prices in 2018, and switched patients to other products, getting ready for the generic entry. Spot the fall in sales...
montyhedge: GSK will lower their price surely and blow Hikma out the water. The real thing or a generic version for the same price. Let the battle begin in 2021.
robertball: I thought HIK would jump a bit higher. I guess it's got it's momentum back now.
Hikma Pharmaceuticals share price data is direct from the London Stock Exchange
ADVFN Advertorial
Your Recent History
Hikma Phar..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20210625 06:08:59